Finerenone (Kerendia) for Chronic Kidney Disease
Date: August 23, 2021
Issue #:
1631Summary:
Finerenone (Kerendia– Bayer), an oral nonsteroidal
mineralocorticoid receptor antagonist (MRA), has
been approved by the FDA to reduce the risk of
sustained eGFR decline, end-stage renal disease,
nonfatal MI, hospitalization for heart failure (HF), and
cardiovascular death in adults with chronic kidney
disease (CKD) associated with type 2 diabetes. It is the
first nonsteroidal MRA to be approved in the US.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: admin Tags: ACE inhibitors ARBs chronic kidney disease finerenone Hypertension Kerendia type 2 diabetes Source Type: research
More News: Cardiology | Cardiovascular | Chronic Kidney Disease | Diabetes | Diabetes Type 2 | Drugs & Pharmacology | Endocrinology | Heart | Heart Failure | Hypertension | Urology & Nephrology